CELU Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.270

Open

1.220

VWAP

1.24

Vol

44.34K

Mkt Cap

35.76M

Low

1.210

Amount

54.98K

EV/EBITDA(TTM)

--

Total Shares

28.84M

EV

75.59M

EV/OCF(TTM)

--

P/S(TTM)

0.73

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Show More

Events Timeline

(ET)

2026-03-12

09:00:00

NexGel Acquires Celularity Biomaterials for $15 Million

2026-03-12

08:40:00

Celularity Signs Strategic Partnership with NEXGEL

2026-03-10 (ET)

2026-03-10

08:50:00

NexGel Signs Agreement to Acquire Celularity's Regenerative Biomaterials

2026-03-10

08:40:00

Celularity Enters Strategic Partnership, Expected Transaction Value Up to $35 Million

2026-02-10 (ET)

2026-02-10

08:40:00

Celularity Receives $12.2 Million in Cash Proceeds

2025-12-31 (ET)

2025-12-31

16:20:00

Celularity Files to Sell 14.08M Shares of Class A Common Stock

2025-12-26 (ET)

2025-12-26

08:40:00

Celularity CEO Comments on CMS Withdrawal of Skin Substitute Coverage Determinations

2025-12-19 (ET)

2025-12-19

16:20:00

Celularity Files to Sell 15.95M Shares of Class A Common Stock

2025-12-18 (ET)

2025-12-18

14:20:00

Celularity Enters $10M Financing Agreement with DoubleLine Capital

2025-10-30 (ET)

2025-10-30

08:17:56

Celularity and DefEYE Collaborate to Enhance Regenerative Treatments in Eye Care

News

moomoo

NEXGEL INC - Agreement Anticipated to Increase Annual Revenue to $35 Million and Achieve Profitability at Closing

moomoo

NEXGEL INC: $15 Million Upfront Cash and Potential $20 Million in Milestone Payments Included in Consideration

moomoo

NEXGEL Reveals Terms for Licensing and Acquiring a Portfolio of Commercial Regenerative Biomaterial Products

seekingalpha

03-10seekingalpha

Celularity Enters Strategic Partnership for Biomaterials

Benzinga

NexGel Expects Revenue to Triple

moomoo

NEXGEL INC ANTICIPATES COMPLETING $14.9 MILLION IN EXTRA FINANCING BY Q1 OR EARLY Q2 2026

Valuation Metrics

The current forward P/E ratio for Celularity Inc (CELU.O) is -0.29, compared to its 5-year average forward P/E of -3.13. For a more detailed relative valuation and DCF analysis to assess Celularity Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-3.13

Current PE

-0.29

Overvalued PE

0.61

Undervalued PE

-6.86

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.28

Current EV/EBITDA

-0.67

Overvalued EV/EBITDA

1.45

Undervalued EV/EBITDA

-6.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

20.62

Current PS

0.52

Overvalued PS

62.64

Undervalued PS

-21.41

Financials

AI Analysis

Annual

Quarterly

Whales Holding CELU

Trading Trends

People Also Watch

Frequently Asked Questions

What is Celularity Inc (CELU) stock price today?

The current price of CELU is 1.24 USD — it has increased 1.64

What is Celularity Inc (CELU)'s business?

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

What is the price predicton of CELU Stock?

Wall Street analysts forecast CELU stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELU is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Celularity Inc (CELU)'s revenue for the last quarter?

Celularity Inc revenue for the last quarter amounts to 5.28M USD, decreased -43.16

What is Celularity Inc (CELU)'s earnings per share (EPS) for the last quarter?

Celularity Inc. EPS for the last quarter amounts to -0.88 USD, increased 20.55

How many employees does Celularity Inc (CELU). have?

Celularity Inc (CELU) has 123 emplpoyees as of March 17 2026.

What is Celularity Inc (CELU) market cap?

Today CELU has the market capitalization of 35.76M USD.